Reimbursement Review Reports

The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Opdivo Nivolumab Metastatic Hepatocellular Carcinoma (HCC) Do not reimburse Complete
Opdivo nivolumab Resectable Non-Small Cell Lung Cancer Reimburse with clinical criteria and/or conditions Complete
Opdivo Nivolumab Metastatic non small cell lung cancer Reimburse with clinical criteria and/or conditions Complete
Opdivo Nivolumab Metastatic Renal Cell Carcinoma Reimburse with clinical criteria and/or conditions Complete
Opdivo Nivolumab Squamous Cell Carcinoma of Head and Neck (SCCHN) Reimburse with clinical criteria and/or conditions Complete
Opdivo Nivolumab Metastatic Melanoma Reimburse with clinical criteria and/or conditions Complete
Opdivo nivolumab Stage IIB or IIC melanoma, adjuvant Reimburse with clinical criteria and/or conditions Complete
Opdivo & Yervoy in combo Nivolumab & Ipilimumab in combo Metastatic Melanoma Reimburse with clinical criteria and/or conditions Complete
Opdivo in combination with Yervoy Nivolumab in combination with Ipilimumab Advanced or Metastatic Renal Cell Carcinoma (RCC). Reimburse with clinical criteria and/or conditions Complete
Opdivo in combination with Yervoy Nivolumab in combination with Ipilimumab NSCLC Reimburse with clinical criteria and/or conditions Complete